Theravance Biopharma Inc (0TB) - Total Liabilities

Latest as of September 2025: €182.78 Million EUR ≈ $213.69 Million USD

Based on the latest financial reports, Theravance Biopharma Inc (0TB) has total liabilities worth €182.78 Million EUR (≈ $213.69 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Theravance Biopharma Inc - Total Liabilities Trend (2014–2024)

This chart illustrates how Theravance Biopharma Inc's total liabilities have evolved over time, based on quarterly financial data. See Theravance Biopharma Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Theravance Biopharma Inc Competitors by Total Liabilities

The table below lists competitors of Theravance Biopharma Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Coretronic TWO:5371	Taiwan	NT$32.56 Billion
Lighthouse Capital Ltd JSE:LTE	South Africa	ZAC725.19 Million
Raisecom Technology Co Ltd SHG:603803	China	CN¥700.26 Million
China Railway Signal & Communication Corporation Limited F:RS3	Germany	€65.85 Billion
J.S. Corrugating Machinery Co Ltd SHE:000821	China	CN¥8.92 Billion
Koppers Holdings Inc NYSE:KOP	USA	$1.33 Billion
Heritage Commerce Corp NASDAQ:HTBK	USA	$5.06 Billion
Grupo Supervielle SA NYSE:SUPV	USA	$6.51 Trillion

Liability Composition Analysis (2014–2024)

This chart breaks down Theravance Biopharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 0TB stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	9.48	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.79	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.44	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Theravance Biopharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Theravance Biopharma Inc (2014–2024)

The table below shows the annual total liabilities of Theravance Biopharma Inc from 2014 to 2024.

Year	Total Liabilities	Change
2024-12-31	€178.62 Million ≈ $208.82 Million	+5.69%
2023-12-31	€169.00 Million ≈ $197.58 Million	+2.06%
2022-12-31	€165.60 Million ≈ $193.60 Million	-76.79%
2021-12-31	€713.39 Million ≈ $834.03 Million	-7.69%
2020-12-31	€772.81 Million ≈ $903.49 Million	+22.15%
2019-12-31	€632.67 Million ≈ $739.65 Million	+3.41%
2018-12-31	€611.82 Million ≈ $715.29 Million	+87.55%
2017-12-31	€326.22 Million ≈ $381.39 Million	+12.87%
2016-12-31	€289.02 Million ≈ $337.90 Million	+406.60%
2015-12-31	€57.05 Million ≈ $66.70 Million	+18.90%
2014-12-31	€47.98 Million ≈ $56.10 Million	--

About Theravance Biopharma Inc

F:0TB Germany Biotechnology

Market Cap

$847.15 Million

€724.62 Million EUR

Market Cap Rank

#9930 Global

#1200 in Germany

Share Price

€14.30

Change (1 day)

+1.42%

52-Week Range

€8.95 - €17.50

All Time High

€38.30